For the development of vaccines against pathogens, Intravacc has designed and developed a platform based on outer membrane vesicles (OMVs) – spherical particles with intrinsic adjuvating properties.
The OMVs can be decorated with immunogenic peptides and/or proteins that will drive effective adaptive immunity. The OMV carrier has been optimized to induce a more effective immune response against these newly introduced antigens. Intravacc also has developed genetic tools to increase the yield of OMVs, to reduce toxicity, and to achieve the desired antigenic composition. Intravacc’s OMV platform is fully scalable and allows for fast and efficient modification of antigen composition, either via genetic modification of the bacterial host or by associating antigens to stockpiled carrier OMVs.
Intravacc’s viral vaccine production process is based on a cGMP-grade, regulatory approved, Vero cell line. This platform is being used for routine large-scale commercial vaccine manufacturing by clients world-wide. In addition, virus seed lots and clinical batches have regularly been produced on the Vero cells, for example Poliovirus, Enterovirus (EV71), and Respiratory Syncytial Virus (RSV).
Intravacc has licensed CimCure's iBoost technology, which can be employed to induce polyclonal antibody responses against cancer-specific antigens. iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance. This treatment strategy has a long-term efficacy and is extremely cost-effective.
NEED MORE INFORMATION?
Subscribe to our news update
Stay up to date with the latest developments, and be the first to receive our news updates and announcements.